MedWatch

Diagnostics company launches first blood test, doubles workforce and eyes profit

Blusense Diagnostics, a spin-out from the Technical University of Denmark (DTU), has launched its first product - a blood test to diagnose Dengue. The company expects to yield profit around 2022 and employ at least 70 people already next year.

In 2017, Filippo Bosco (middle left), CEO of Blusense Diagnostics, received an innovation prize in Malaysia and DKK 670,000. Photo: Blusense Diagnostics / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles